Status: Recruiting
AK129 Combination Therapy for Advanced Solid Tumors
This is an open, multicenter phase Ib/II clinical study. The goal of this study is to confirm the Phase II recommended dose (RP2D) of AK129 combinations for advanced solid tumors and evaluate the safety and efficacy of AK129 combinations for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal adenocarcinoma (CRC), and other advanced solid tumors.
Participants needed: 230
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: AkesoUpdated: Jun 3, 2025Locations: 1
Eligibility criteria
Be able and willing to provide written informed consent and to comply with all r... [+8]
Histologically or cytologically confirmed the presence of small cell carcinoma c... [+10]